ReviewMarine drugs2015
Aeroplysinin-1, a Sponge-Derived Multi-Targeted Bioactive Marine Drug.
Review in Marine drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 293 citations in OpenAlex.
- Mitochondrial involvement in PC: improving therapeutic strategies.Frontiers in pharmacology · 2025Review
- Article
- Article
- Impact of Marine Chemical Ecology Research on the Discovery and Development of New Pharmaceuticals.Marine drugs · 2023Review
- The Sponge-Derived Brominated Compound Aeroplysinin-1 Impairs the Endothelial Inflammatory Response through Inhibition of the NF-κB Pathway.Marine drugs · 2022Article
- Targeted Isolation of Antibiotic Brominated Alkaloids from the Marine SpongeMarine drugs · 2022Article
- The Antileukemic and Anti-Prostatic Effect of Aeroplysinin-1 Is Mediated through ROS-Induced Apoptosis via NOX Activation and Inhibition of HIF-1a Activity.Life (Basel, Switzerland) · 2022Article
- Screening of diverse marine invertebrate extracts identified Lissoclinotoxin F, Discodermin B, and other anti-Mycobacterium tuberculosis active compounds.The Journal of antibiotics · 2022Article
- Promising antiparasitic agents from marine sponges.Saudi journal of biological sciences · 2022Review
- Pharmacological Activities of Extracts and Compounds Isolated from Mediterranean Sponge Sources.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Matrix metalloproteinase contribution in management of cancer proliferation, metastasis and drug targeting.Molecular biology reports · 2021Review
- The Anti-Viral Applications of Marine Resources for COVID-19 Treatment: An Overview.Marine drugs · 2021Review
- Naturally Formed Chitinous Skeleton Isolated from the Marine DemospongeMaterials (Basel, Switzerland) · 2021Article
- Potentials of marine natural products against malaria, leishmaniasis, and trypanosomiasis parasites: a review of recent articles.Infectious diseases of poverty · 2021Review
- Review
- Marine biomimetics: bromotyrosines loaded chitinous skeleton as source of antibacterial agents.Applied physics. A, Materials science & processing · 2021Article
- Marine Organisms from the Yucatan Peninsula (Mexico) as a Potential Natural Source of Antibacterial Compounds.Marine drugs · 2020Article
- Review
- A marine sponge associated fungal metabolite monacolin X suppresses angiogenesis by down regulating VEGFR2 signaling.RSC advances · 2019Article
- Exploring the Antiangiogenic Potential of Solomonamide A Bioactive Precursors: In VitroMarine drugs · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organisms lacking external defense mechanisms have developed chemical defense strategies, particularly through the production of secondary metabolites with antibiotic or repellent effects. Secondary metabolites from marine organisms have proven to be an exceptionally rich source of small molecules with pharmacological activities potentially beneficial to human health. (+)-Aeroplysinin-1 is a secondary metabolite isolated from marine sponges with a wide spectrum of bio-activities. (+)-Aeroplysinin-1 has potent antibiotic effects on Gram-positive bacteria and several dinoflagellate microalgae causing toxic blooms. In preclinical studies, (+)-aeroplysinin-1 has been shown to have promising anti-inflammatory, anti-angiogenic and anti-tumor effects. Due to its versatility, (+)-aeroplysinin-1 might have a pharmaceutical interest for the treatment of different pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.